TET2 and acute myeloid leukemia: We found no significant difference in OS related to the presence or absence of CK (p = 0.252), ICC MR mutations (p = 0.252), DNMT3A (p = 0.264), TET2 (p = 0.264), and IDH1 (p = 0.183) among MK AML patients (Table 3).